<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11526">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01813006</url>
  </required_header>
  <id_info>
    <org_study_id>2011/899(REK)</org_study_id>
    <secondary_id>2012-000505-68</secondary_id>
    <nct_id>NCT01813006</nct_id>
  </id_info>
  <brief_title>Effect of Omega-3 Fatty Acid on Endothelial Function</brief_title>
  <official_title>Effect of Omega-3 Polyunsaturated Fat on Endothelial Function and Inflammatory Parameters in Familial Hypercholesterolemia - a Double Blind, Placebo-controlled Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordlandssykehuset HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pronova BioPharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nordlandssykehuset HF</source>
  <oversight_info>
    <authority>Norway: The National Committee for Medical and Health Research  Ethics in Norway</authority>
    <authority>Norway: Norwegian Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background

      Familial hypercholesterolemia (FH) is an inherited disease in which the level of bad
      cholesterol (LDL-cholesterol) is increased, leading to an increase in coronary heart disease
      even if adequately treated with cholesterol lowering medication (statins). Polyunsaturated
      fatty acids (PUFA) including omega-3 is known to  affect the risk for coronary disease,
      however its effect on patients with FH is not known.

      The purpose of the study is to assess the effect of PUFA on patients with FH, with regard to
      inflammation measured in the blood and the effect on the blood vessels`ability to relax
      (endothelial function) by means of tonometry.

      Hypothesis

      Treatment with 4 grams of PUFA a day for 4 months will lead to an improvement in the
      endothelial function, and the treatment will also lead to a decrease in in several markers
      of inflammation and in lipids in the blood.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reactive Hyperemia Index (RHI)</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reactive Hyperemia Index (RHI) is a measure for endothelial function by means of tonometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reactive Hyperemia Index (RHI)</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure of endothelial function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reactive Hyperemia Index (RHI)</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure of endothelial function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reactive Hyperemia Index (RHI)</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure of endothelial function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Markers of inflammation</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serological markers of inflammation including cytokines, C-reactive protein (CRP) and complement factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serological markers of inflammation including cytokines, CRP and complement factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serological markers of inflammation including cytokines, CRP and complement factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serological markers of inflammation including cytokines, CRP and complement factors</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Lipid parameters</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Different fractions of lipids in the blood including LDL-cholesterol, HDL cholesterol, triglycerides and their subfractions</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipid parameters</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Different fractions of lipids in the blood including LDL-cholesterol, HDL cholesterol, triglycerides and their subfractions</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipid parameters</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Different fractions of lipids in the blood including LDL-cholesterol, HDL cholesterol, triglycerides and their subfractions</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipid parameters</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Different fractions of lipids in the blood including LDL-cholesterol, HDL cholesterol, triglycerides and their subfractions</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Omega-3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omega-3 fatty acids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo/olive oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3</intervention_name>
    <arm_group_label>Omega-3</arm_group_label>
    <other_name>Omacor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>olive oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  documented familial hypercholesterolemia

          -  age 18-60 years

          -  on statin treatment for at least 12 months

        Exclusion Criteria:

          -  pregnancy or planned pregnancy

          -  breast feeding

          -  cancer

          -  non-compliance

          -  PUFA/omega-3 &lt; 3 months before inclusion
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Knut T Lappegård, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nordland Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Knut T Lappegård, MD, PhD</last_name>
    <phone>004775534000</phone>
    <email>knut.tore.lappegard@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anders W Hovland, MD, PhD</last_name>
    <phone>004775534000</phone>
    <email>anders.w.hovland@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Internal Medicine, Nordland Hospital</name>
      <address>
        <city>Bodø</city>
        <zip>8011</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Knut T Lappegård, MD, PhD</last_name>
      <phone>004775534000</phone>
      <email>knut.tore.lappegard@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Anders W Hovland, MD, PhD</last_name>
      <phone>004775534000</phone>
      <email>anders.w.hovland@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Knut T Lappegård, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anders W Hovland, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 14, 2013</lastchanged_date>
  <firstreceived_date>March 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
